However, the exact contribution of semaglutide-induced weight loss to kidney stone prevention requires further study for a clearer understanding
Health Canada is currently reviewing nine applications from pharmaceutical companies seeking approval to sell generic versions, including submissions from Sandoz, Apex, Teva Canada, Taro Pharmaceuticals, and Aspen Pharmacare Canada. Expected Pricing for Generics: Industry experts predict dramatic price reductions once generics arrive
Wegovy is currently the only form of semaglutide thats FDA-approved for weight loss
Carmot Therapeutics closes $160 million series D financing to Advance Clinical Pipeline of Novel Incretin receptor modulators
Thank you In all likelihood, this generic version could be priced far lower than other Indian alternatives, helping to offset lower profits in the domestic market through premium pricing in export markets ?